Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

521. A simple risk score using routine data for predicting cardiovascular disease in primary care

A simple risk score using routine data for predicting cardiovascular disease in primary care 20822683 2010 09 08 2010 12 10 2016 11 22 1478-5242 60 577 2010 Aug The British journal of general practice : the journal of the Royal College of General Practitioners Br J Gen Pract A simple risk score using routine data for predicting cardiovascular disease in primary care. e327-34 10.3399/bjgp10X515098 Population-based screening for cardiovascular disease (CVD) risk, incorporating blood tests (...) ):1475-82 18573856 Fam Pract. 2008 Jun;25(3):191-6 18515811 BMJ. 2008;337:a1395 18755771 BMJ. 2009;339:b2584 19584409 Diabetes Metab Res Rev. 2000 May-Jun;16(3):164-71 10867715 Adult Aged Cardiovascular Diseases etiology Female Hospitalization statistics & numerical data Humans Male Middle Aged Primary Health Care Prospective Studies Risk Assessment Risk Factors PMC2913758 2010 9 9 6 0 2010 9 9 6 0 2010 12 14 6 0 ppublish 20822683 10.3399/bjgp10X515098 PMC2913758

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

522. No beneficial effects of pine bark extract on cardiovascular disease risk factors

No beneficial effects of pine bark extract on cardiovascular disease risk factors 20876405 2010 09 29 2010 10 28 2010 09 29 1538-3679 170 17 2010 Sep 27 Archives of internal medicine Arch. Intern. Med. No beneficial effects of pine bark extract on cardiovascular disease risk factors. 1541-7 10.1001/archinternmed.2010.310 Although modifiable cardiovascular disease risk factors are common, some patients eschew conventional drug treatments in favor of natural alternatives. Pine bark extract (...) , a dietary supplement source of antioxidant oligomeric proanthocyanidin complexes, has multiple putative cardiovascular benefits. Studies published to date about the supplement have notable methodological limitations. We randomized 130 individuals with increased cardiovascular disease risk to take 200 mg of a water-based extract of pine bark (n = 64; Toyo-FVG, Toyo Bio-Pharma, Torrance, California; Shinyaku Co, Ltd, Saga, Japan; also marketed as Flavagenol in Japan) or placebo (n = 66) once per day

EvidenceUpdates2010

523. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.

Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. OBJECTIVE: To quantify associations of chronic kidney disease stages with major cardiovascular disease and non-vascular mortality in the general adult population. DESIGN: Prospective population based cohort study. SETTING: Reykjavik, Iceland. PARTICIPANTS: 16 958 people aged 33-81 years without manifest vascular disease and with available information on stage (...) glomerular filtration rate 75-89 ml/min/1.73 m(2) and no proteinuria), people with lower renal function within the normal range of glomerular filtration rate did not have significantly higher risk of coronary heart disease. By contrast, in 1210 (7%) participants with chronic kidney disease at entry, hazard ratios for coronary heart disease, adjusted for several conventional cardiovascular risk factors, were 1.55 (95% confidence interval 1.02 to 2.35) for stage 1, 1.72 (1.30 to 2.24) for stage 2, 1.39 (1.22 to 1.58

BMJ2010 Full Text: Link to full Text with Trip Pro

524. Do the Joint British Society (JBS2) guidelines on prevention of cardiovascular disease with respect to plasma glucose improve risk stratification in the general population? Prospective cohort study

Do the Joint British Society (JBS2) guidelines on prevention of cardiovascular disease with respect to plasma glucose improve risk stratification in the general population? Prospective cohort study 20536951 2010 06 11 2010 11 05 2016 11 25 1464-5491 27 5 2010 May Diabetic medicine : a journal of the British Diabetic Association Diabet. Med. Do the Joint British Society (JBS2) guidelines on prevention of cardiovascular disease with respect to plasma glucose improve risk stratification (...) in the general population? Prospective cohort study. 550-5 10.1111/j.1464-5491.2010.02921.x British guidelines on vascular disease prevention recommend adding a random (casual) blood glucose measurement to a lipid profile in those aged > or = 40 years. To assess this recommendation, we compared the predictive value of a risk model based on the Framingham risk score alone to one which additionally included information on fasting blood glucose, with respect to incident coronary heart disease (CHD) over 11

EvidenceUpdates2010

525. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs

The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs

CMA Infobase (Canada)2010

526. Whole-Grain, Cereal Fiber, Bran, and Germ Intake and the Risks of All-Cause and Cardiovascular Disease-Specific Mortality Among Women With Type 2 Diabetes Mellitus

Whole-Grain, Cereal Fiber, Bran, and Germ Intake and the Risks of All-Cause and Cardiovascular Disease-Specific Mortality Among Women With Type 2 Diabetes Mellitus 20458012 2010 05 25 2010 06 17 2016 10 19 1524-4539 121 20 2010 May 25 Circulation Circulation Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus. 2162-8 10.1161/CIRCULATIONAHA.109.907360 Although whole-grain consumption (...) has been associated with a lower risk of cardiovascular diseases (CVD) and mortality in the general population, the association of whole grain with mortality in diabetic patients remains to be determined. This study investigated whole grain and its components cereal fiber, bran, and germ in relation to all-cause and CVD-specific mortality in patients with type 2 diabetes mellitus. We followed 7822 US women with type 2 diabetes mellitus in the Nurses' Health Study. Dietary intakes and potential

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

527. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes

Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes 20332353 2010 05 28 2010 08 31 2016 12 15 1935-5548 33 6 2010 Jun Diabetes care Diabetes Care Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes. 1153-8 10.2337/dc09-2090 To examine the effect of a lifestyle intervention (...) to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45-76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

528. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey.

Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. OBJECTIVE: To examine if self reported toothbrushing behaviour is associated with cardiovascular disease and markers of inflammation (C reactive protein) and coagulation (fibrinogen). DESIGN: National population based survey. SETTING: Scottish Health Survey, which draws a nationally representative sample of the general population living in households in Scotland. PARTICIPANTS: 11,869 men (...) and women, mean age 50 (SD 11). MAIN OUTCOME MEASURES: Oral hygiene assessed from self reported frequency of toothbrushing. Surveys were linked prospectively to clinical hospital records, and Cox proportional hazards models were used to estimate the risk of cardiovascular disease events or death according to oral hygiene. The association between oral hygiene and inflammatory markers and coagulation was examined in a subsample of participants (n=4830) by using general linear models with adjustments

BMJ2010 Full Text: Link to full Text with Trip Pro

529. Combined effects of smoking and peripheral arterial disease on all-cause and cardiovascular disease mortality in a Chinese male cohort

Combined effects of smoking and peripheral arterial disease on all-cause and cardiovascular disease mortality in a Chinese male cohort 20206811 2010 03 08 2010 04 13 2012 10 03 1097-6809 51 3 2010 Mar Journal of vascular surgery J. Vasc. Surg. Combined effects of smoking and peripheral arterial disease on all-cause and cardiovascular disease mortality in a Chinese male cohort. 673-8 10.1016/j.jvs.2009.09.024 Smoking is a major risk factor for peripheral arterial disease (PAD), and PAD (...) is associated with all-cause and cardiovascular disease (CVD) mortality. The objective of this study was to determine the combined effects of smoking and PAD on all-cause and CVD mortality. A total of 1979 males 35 years of age or older were enrolled from eight university-affiliated hospitals in Beijing and Shanghai in 2004, with both smoking status and PAD diagnosis obtained, 1712 of them had complete follow-up data. Mortality data were obtained from all participants between December 2007 and February 2008

EvidenceUpdates2010

530. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study.

Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. OBJECTIVE: To estimate the potential population impact of different screening strategies for identifying and treating people at high risk of cardiovascular disease, including strategies using routine data for cardiovascular risk stratification, in light of the UK government's recommended national strategy to screen all adults aged 40-74 (...) for cardiovascular risk. DESIGN: Modelling study using data from a prospective cohort, EPIC-Norfolk (European Prospective Investigation of Cancer-Norfolk). SETTING: An English county. PARTICIPANTS: 16,970 men and women aged 40-74 and free from cardiovascular disease and diabetes at baseline. MAIN OUTCOME MEASURES: The main outcomes were the population attributable fraction, the number needed to screen to prevent one new case of cardiovascular disease, the number needed to treat to prevent one new case

BMJ2010 Full Text: Link to full Text with Trip Pro

531. Childhood cognition and risk factors for cardiovascular disease in midadulthood: the 1958 British Birth Cohort Study

Childhood cognition and risk factors for cardiovascular disease in midadulthood: the 1958 British Birth Cohort Study 19910352 2009 12 16 2010 01 11 2017 02 20 1541-0048 100 1 2010 Jan American journal of public health Am J Public Health Childhood cognition and risk factors for cardiovascular disease in midadulthood: the 1958 British Birth Cohort Study. 129-36 10.2105/AJPH.2008.155564 We sought to establish whether associations between childhood cognition and risk factors for cardiovascular (...) disease in adulthood are explained by common causes, or adult social position or health behavior. We analyzed associations between cognition at age 11 and cardiovascular disease risk factors at age 45 in the 1958 British birth cohort (n=9377), with and without adjustment for covariates. General ability was inversely associated with systolic and diastolic blood pressure, glycosylated hemoglobin, triglycerides (in women), body mass index, and waist circumference. Systolic blood pressure decreased

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

532. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) 19540640 2009 10 26 2009 11 16 2015 11 19 1523-6838 54 5 2009 Nov American journal of kidney diseases : the official journal of the National Kidney Foundation Am. J. Kidney Dis. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes (...) Study (CARDS). 810-9 10.1053/j.ajkd.2009.03.022 We examined whether atorvastatin affects diabetic kidney disease and whether the effect of atorvastatin on cardiovascular disease (CVD) varies by kidney status in patients with diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) randomized placebo-controlled trial. Patients with type 2 diabetes and no prior CVD (n = 2,838). Random allocation to atorvastatin, 10 mg/d, or placebo, with a median follow-up of 3.9 years. Estimated

EvidenceUpdates2010

533. Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease. A Randomized Trial

Efficacy and Safety of Varenicline for Smoking Cessation in Patients With Cardiovascular Disease. A Randomized Trial 20048210 2010 01 19 2010 03 18 2016 12 15 1524-4539 121 2 2010 Jan 19 Circulation Circulation Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. 221-9 10.1161/CIRCULATIONAHA.109.869008 Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial alpha4beta2 nicotinic (...) acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown. A multicenter, randomized, double-blind, placebo-controlled trial compared the efficacy and safety of varenicline with placebo for smoking cessation in 714 smokers with stable cardiovascular disease. Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counseling, for 12 weeks. Follow-up lasted 52 weeks

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

534. Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease.

Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. BACKGROUND: The U.S. diet is high in salt, with the majority coming from processed foods. Reducing dietary salt is a potentially important target for the improvement of public health. METHODS: We used the Coronary Heart Disease (CHD) Policy Model to quantify the benefits of potentially achievable, population-wide reductions in dietary salt of up to 3 g per day (1200 mg of sodium per day). We estimated the rates (...) and costs of cardiovascular disease in subgroups defined by age, sex, and race; compared the effects of salt reduction with those of other interventions intended to reduce the risk of cardiovascular disease; and determined the cost-effectiveness of salt reduction as compared with the treatment of hypertension with medications. RESULTS: Reducing dietary salt by 3 g per day is projected to reduce the annual number of new cases of CHD by 60,000 to 120,000, stroke by 32,000 to 66,000

NEJM2010 Full Text: Link to full Text with Trip Pro

535. JUPITER randomised controlled trial: Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men

JUPITER randomised controlled trial: Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men Article Text Therapeutics JUPITER randomised controlled trial Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women

Evidence-Based Medicine (Requires free registration)2010

536. Lifestyle-focused interventions at the workplace to reduce the risk of cardiovascular disease: a systematic review

Lifestyle-focused interventions at the workplace to reduce the risk of cardiovascular disease: a systematic review Lifestyle-focused interventions at the workplace to reduce the risk of cardiovascular disease: a systematic review Lifestyle-focused interventions at the workplace to reduce the risk of cardiovascular disease: a systematic review Groeneveld IF, Proper KI, van der Beek AJ, Hildebrandt VH, van Mechelen W CRD summary This generally well-conducted review found strong evidence (...) for the effectiveness of workplace lifestyle interventions on body fat and (in populations at risk of cardiovascular disease) on body weight. No information was available on lifestyle change and detailed analysis of intervention components. The authors’ conclusions were supported by the data presented, but data-related limitations should be considered when interpreting the findings. Authors' objectives To assess the effects of workplace interventions targeting lifestyle changes on the main biological risk factors

DARE.2010

537. Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness

Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness Mujoomdar M, Clark M, Nkansah E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Mujoomdar M, Clark M, Nkansah E. Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' objectives Coronary artery disease (CAD) is a leading cause of morbidity and mortality in the Western world. Early detection, followed by treatment, may limit disease progression. Cardiac imaging using positron emission tomography (PET) can be used to evaluate CAD

Health Technology Assessment (HTA) Database.2010

538. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels

Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels Miller ER, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E CRD (...) summary This review concluded that folic acid supplementation had no effect on cardiovascular disease, mortality and stroke. Stratified analysis showed higher risk of cardiovascular disease with folic acid with high baseline homocysteine level and lower risk with lower homocysteine. The authors’ conclusions on the overall outcomes appeared reasonable, but those for stratified analyses should be treated with caution. Authors' objectives To assess the effects of folic acid supplementation

DARE.2010

539. Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease

Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Angiotensin receptor blockers associated with decreased incidence and progression of dementia in older men with cardiovascular disease Article Text Prognosis Angiotensin receptor blockers associated with decreased incidence

Evidence-Based Mental Health2010

540. Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus: a systematic review of randomized controlled trials

Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus: a systematic review of randomized controlled trials Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes mellitus: a systematic review of randomized controlled trials Multifactorial lifestyle interventions in the primary and secondary prevention of cardiovascular disease and type 2 diabetes (...) ) that compared lifestyle interventions in people with or at increased risk of type 2 diabetes or coronary heart disease to a less intensive intervention or usual care were eligible for inclusion. Trials needed a minimum follow-up of six months. Interventions had to consist of elements aimed at diet, exercise and stress management/relaxation. The primary outcomes of interest were mortality, cardiovascular events and diabetic secondary complications. Secondary prevention studies were included if they reported

DARE.2010